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Selective targeted delivery of TNF to tumor blood vessels α   
 
Laura Borsi, Enrica Balza, Barbara Carnemolla, Francesca Sassi, Patrizia Castellani, Alexander Berndt, 
Hartwig Kosmehl, Attila Birò , Annalisa Siri, Paola Orecchia, Jessica Grassi, Dario Neri, and Luciano Zardi    
 
We sought to enhance the selective toxicity of tumor necrosis factor alpha (TNF α) to permit its systemic use 
in cancer therapy. Because ligand-targeted therapeutics have proven successful in improving the selective 
toxicity of drugs, we prepared a fusion protein (L19mTNF α) composed of mouse TNF α  and a high-affinity 
antibody fragment (L19 scFv) to the extradomain B (ED-B) domain of fibronectin, a marker of angiogenesis. 
L19mTNFα was expressed in mammalian cells, purified, and characterized. L19mTNFα  was an 
immunoreactive and biologically active homotrimer. Radiolabeled L19mTNF α selectively targeted tumor 
neovasculature in tumorbearing mice, where it accumulated selectively and persistently (tumor-to-blood ratio 
of the percentage of injected dose per gram [%ID/g] of 700, 48 hours from injection). L19mTNF α showed a 
greater anticancer therapeutic activity than both mTNF α and TN11mTNF α, a control fusion protein in 
which an antibody fragment, irrelevant in the tumor model used, substituted for L19. This activity was 
further dramatically enhanced by its combination with melphalan or the recently reported fusion protein L19-
IL2. In conclusion, L19mTNF α allows concentrating therapeutically active doses of TNF α at the tumor 
level, thus opening new possibilities for the systemic use of TNF α in cancer therapy.   
 
Introduction  
During tumor progression the microenvironment surrounding tumor cells undergoes extensive modifications 
that generate a “tumoral environment” which could ultimately represent a suitable target for antibody-based 
tumor therapy.1 In fact, the concept that the altered tumor microenvironment is itself a carcinogen that can 
be targeted is increasingly gaining consensus. Molecules that are able to effectively deliver therapeutic 
agents to the tumor microenvironment thus represent promising and important new tools for cancer 
therapy.1-3 Fibronectin is an extracellular matrix (ECM) component that is widely expressed in a variety of 
healthy tissues and body fluids. Different fibronectin (FN) isoforms can be generated by the alternative 
splicing of the FN pre-mRNA, a process modulated by cytokines and extracellular pH.4-7 The complete type 
III repeat extradomain B (ED-B) may be entirely included or omitted in the FN molecule.8 ED-B is highly 
conserved in different species, having 100% homology in all mammalians thus far studied (human, rat, 
mouse) and 96% homology with a similar domain in chicken. The FN isoform containing ED-B (B-FN) is 
undetectable immunohistochemically in healthy adult tissues, with the exception of tissues undergoing 
physiologic remodeling (eg, endometrium and ovary) and during wound healing.5,9 By contrast, its 
expression in tumors and fetal tissues is high.5 Furthermore, it was demonstrated that B-FN is a marker of 
angiogenesis10,11 and that endothelial cells invading tumor tissues migrate along ECM fibers containing B-
FN.12 We reported on the possibility to selectively target tumoral vasculature, both in experimental tumor  
models and in patients with cancer, using a human recombinant antibody, L19 scFv, specific for B-FN.12-19 
This observation paved the way for the antibody’s use in both in vivo diagnostic (immunoscintigraphy) and 
therapeutic approaches entailing the selective delivery of radionuclides or toxic agents to tumoral 
vasculature. In addition, Birchler et al 20 showed that L19, chemically coupled to a photosensitizer, 
selectively accumulates in the newly formed blood vessels of the angiogenic rabbit cornea model and, after 
irradiation with near infrared light, mediates the complete and selective occlusion of ocular neovasculature. 
More recently, Nilsson et al 21 reported that the immunoconjugate of L19 with the extracellular domain of 
tissue factor mediates selective infarction in different types of murine tumor models. Furthermore, the 
cytokines interleukin 2 (IL-2) and IL-12 have both shown an enhanced therapeutic efficacy if delivered as 
fusion proteins with L19.22,23 Finally, because L19 reacts equally well with mouse and human ED-B, it can 
be used for both preclinical and clinical studies. Tumor necrosis factor alpha ( TNF α) is a pleiotropic 
cytokine with antitumoral activity24 composed of 3 noncovalently linked TNF α monomers, each of about 
17.5 kDa, that yield a compact bell-shaped homotrimer.25 TNF α exerts its effects in tumors mainly on the 
endothelium of the tumor-associated vasculature,26,27 with increased permeability, up-regulation of tissue 
factor, fibrin deposition and thrombosis, and massive destruction of the endothelial cells.28-33 Moreover, 
treatment of tumor-bearing mice with intravenous injection of TNF α induces a significant reduction of the 
interstitial fluid pressure of the tumor,34 a process which is instrumental to increasing the concentration of 
antitumoral agents at the tumor site.28,35-37 The systemic administration of large, therapeutically effective, 
doses of TNF α is not possible, however, because of the unacceptably high levels of systemic toxicity it 
induces. For this reason, until today, only loco-regional therapies, such as “isolated limb perfusion” (ILP),38 
have been used. Improved tumor response rates were achieved in patients with in transit melanoma 
metastases, using local perfusions of TNF α  in combination with -interferon and melphalan.38 Moreover, 
ILP with melphalan and TNF α resulted in limb salvage in patients with soft-tissue sarcoma.39 A number 
of approaches are presently under investigation to improve the therapeutic effects and to reduce the toxic 
side effects of systemically administered TNF α. These strategies include the production of engineered TNF 
α  mutants,40 the encapsulation of TNF α  in long circulating liposomes,41 and the selective delivery to and 
concentration in tumors of TNF α  through its coupling to specific ligands.42-44 Here we report the ligand-
targeting treatment of tumor-bearing mice using the fusion protein L19mTNF α.    
 
Materials and methods    
Preparation of L19mTNF α  and TN11mTNF α  fusion proteins   
Mouse TNF α  cDNA covering the sequence coding for the 156 amino acid (aa)–long secreted form of 
mTNF (Swissprot accession no. P06804)45 was obtained by reverse transcription–polymerase chain 
reaction (RT-PCR; Titan One Tube RT-PCR System; Roche Diagnostics, Mannheim, Germany) by using 
Balb/C mouse spleen total RNA as template and the primers BC-742 and BC-752. The forward BC-742 
primer (sequence, ctcgaattctcttcctcatcgggtagtagctcttccggctcatcgtccagcggcctcagatcatcttctcaaaattcg) contained 
the EcoRI restriction enzyme sequence, a 45–base pair (bp) sequence encoding for a 15 amino acid linker 
(SSSSG)3, and the sequence coding for the first 8 amino acids of the mature murine TNF α . The reverse 
BC-752 primer (sequence, ctcgcggccgctcatcacagagcaatgactccaaagta) contained the sequence of the last 7 
amino acids of murine TNF α , 2 stop codons, and the NotI restriction enzyme sequence (Figure 1B). The 
genomic sequence of the signal secretion leader peptide was obtained by HindIII and ApaLI digestion of the 
vector pUT-SEC,46 kindly provided by Dr Oscar Burrone (ICGEB, Trieste, Italy). The cDNAof the scFv 
L1912 was obtained by using Pwo enzymes (Roche Diagnostics), the primers BC-618 (containing the ApaLI 
restriction enzyme sequence) and BC-679 (containing the EcoRI restriction enzyme sequence) already 
reported by Carnemolla et al,22 and the DNA vector pDNEK-L19 as template. The cDNA sequence of the 
scFv TN1147 was obtained using Pwo enzymes (Roche Diagnostics) and the primers BC-773 (forward 
sequence, ctcgtgtgcactcgcaggtgcagctggtgcagtct) containing the ApaLI restriction enzyme sequence and BC-
774 (reverse sequence, ctcgaattcacctaggacggtcagcttggt) containing the EcoRI restriction enzyme sequence, 
and the DNA vector reported by Carnemolla et al47 as template. The cDNA constructs depicted in Figure 1B 
(signal peptide, scFv L19 or TN11, and linker-mTNF) were cloned in pCDNA3.1 mammalian expression 
vector (Invitrogen, Groningen, The Netherlands). The clones were sequenced on both strands using the ABI 
PRISM dRhodamine Terminator Cycle Sequencing Ready Reaction Kit (Perkin Elmer, Foster City, CA). All 
restriction enzymes (REs) were from Roche Diagnostics.    
 
Expression, purification, and characterization of the L19mTNF α  and TN11mTNF α  fusion proteins   
SP2/0 murine myeloma cells (American Tissue Type Culture Collection, ATCC, Rockville, MD) were 
transfected with the use of Fugene 6 Transfection Reagent (Roche Diagnostics) following the manufacturer’s 
recommendations and selected in the presence of 500 g/mL G418 (Calbiochem, San Diego, CA). The 
supernatants of the G418 resistant clones were screened for the production of the fusion proteins by using the 
enzyme-linked immunoabsorbent assay (ELISA) and the recombinant peptide composed of the type III 
homology repeats 7B8915 for L19, or the recombinant peptide Tenascin-C (TN-C)(A-D) for TN11.47 A 
rabbit anti mTNF α  polyclonal (PeproTech EC, London, England) was used as secondary antibody and a 
peroxidase-conjugated antirabbit immunoglobulin G (IgG) polyclonal (Pierce, Rockford, IL) as tertiary 
antibody. The biologic activity of TNF α was determined by using the cytotoxicity test on mouse L-M 
fibroblasts (ATCC), in the presence of 2 g/mL actinomycin D (Sigma Chemical, St Louis, MO) described 
by Corti et al48 and 0.07 to 53 pM recombinant mouse TNF α  (rmTNF α ; 2  107 U/mg; kindly provided 
by Dr Corti, Dibit, Milano, Italy). Quadruplicates were done, and the results were expressed as the 
percentage of cell viability compared with the controls (cells treated with actinomycin D only). 
Immunoaffinity chromatography on ED-B15 and TN-C(A-D)47 conjugated to Sepharose 4B (Amersham 
Pharmacia Biotech, Uppsala, Sweden) was used to purify L19mTNF and TN11mTNF, respectively, from 
the conditioned media of the cells expressing the fusion proteins. The homotrimers (Figure 1A) of both 
fusion proteins were further purified by molecular exclusion chromatography (Superdex 200; Amersham 
Pharmacia Biotech) and subsequently analyzed under reducing conditions by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS-PAGE; 4%-18% gradient) (Figure 1C) and in native conditions by 
fast-protein liquid chromatography on a Superdex 200 column (Figure 1D). The radius (nanometers) and the 
molecular weight (MW; kilodaltons) of the purified fusion proteins in phosphate-buffered saline (PBS; 20 
mM NaH2PO4, 150 mM NaCl, pH 7.4) were determined at 25°C, using the DynaPro Molecular Sizing 
Instrument (ProteinSolutions, Lakewood, NJ).    
 
Histologic analyses   
Tissue samples were both paraffin embedded for histologic analysis performed as reported by Carnemolla et 
al22 and snap-frozen for immunohistochemistry. For immunocytochemistry, L-M murine fibroblasts were 
grown in Chamberslide (Nunc, Roskilde, Denmark) and then methanol fixed. Immunohistochemistry on 4-
m cryostat sections and immunocytochemistry were performed as reported by Carnemolla et al.22 The 
following primary antibodies were used: monoclonal rat antimouse Ki-67 (clone TEC-3; DAKO A/S, 
Glostrup, Denmark), monoclonal rat antimouse CD31 (clone 13.3; kindly supplied by A. Mantovani; Mario 
Negri Institute, Milan, Italy), and the fusion proteins L19mTNF and TN11mTNF. To reveal 
immunoreactivity the following antibodies were used: rabbit anti-mTNF polyclonal (PeproTech) followed 
by biotinylated goat antimouse IgG polyclonal (BioSpa, Milan, Italy) and mouse antirat IgG2b and IgG1/2a 
(BD Biosciences, Heidelberg, Germany). Sections were then counterstained with hematoxylin and mounted 
permanently. Quantitative image analysis for the area of vital (non-necrotic) tumor tissue (tumor cell 
viability) and quantitative immunohistochemistry for blood vessel density were carried out by computer-
aided image analysis by using the image processing and analysis system Quantimet 600 and Qwin software 
(Leica, Heidelberg, Germany), and the results were expressed as percentage of the whole measurement area, 
as reported by Carnemolla et al.22 For each animal group the mean value and SE of all measurement results 
were calculated. The tumor cell viability (percentage) was obtained by dividing the tumor cell viability after 
treatments by the tumor cell viability of the respective controls, considered 100%. The blood vessel density 
was assessed following the criteria of Weidner.49 Apoptotic cells were detected on dewaxed paraffin 
sections by using the TUNEL (terminal deoxynucleotidyl transferase mediated dUTP-fluorescein nick-end 
labeling) according to Gavriely et al,50 applying the In Situ Cell Death Detection Kit/AP (Roche). Anegative 
control was included in each experimental setup by omitting the terminal deoxynucleotidyl transferase from 
the TUNEL reaction mixture.51    
 
Animal tumor models   
F9 mouse embryonal teratocarcinoma cells (ATCC), WEHI-164 mouse fibrosarcoma cells (ECACCC; 
Sigma Aldrich, Milan, Italy), and C51 mouse colon adenocarcinoma cells52 (kindly provided by Dr M. P. 
Colombo, Milan, Italy) were subcutaneously implanted (3  106) in immunocompetent syngeneic mice (129 
strain for F9 and Balb/C for WHEI-164 and C51). All mice were 8 to 10 weeks old and purchased from 
Harlan UK (Oxon, United Kingdom). All studies were performed when the tumors reached a volume of 0.3 
to 0.4 cm3. The tumor volume was determined with the following formula: (d)2  D  0.52, where d and D 
are the short and long dimensions (centimeters) of the tumor, respectively, measured with a caliper.12 
Housing, treatment, and killing of animals followed national legislative provisions (Italian law no. 116 of 27 
January 1992) for the protection of animals used for scientific purposes.    
 
Biodistribution experiments, microautoradiography, and blood clearance rate   
Radioiodination of the fusion proteins was achieved as reported by Borsi et al.18 The radioactivity was 
established by using a RIASTAR -counter (Packard Instruments, Milan, Italy). After labeling, the 
Superdex 200 profile and the immunoreactivity test were performed.18 Nonspecific accumulation of 
125Iodine in the stomach and concentration in thyroid was blocked as reported by Borsi et al.18 Tumor-
bearing mice were injected in the tail vein with the radioiodinated fusion proteins in 100 L PBS. Groups of 
3 animals were killed at 3, 6, 24, and 48 hours after injection. The different organs, including tumor and 
blood, were taken and weighed, and the radioactivity was counted to determine the percentage of injected 
dose per gram (%ID/g). Tissue samples were then fixed with 5% formaldehyde in PBS, pH 7.4, and 
processed for microautoradiographies, according to Tarli et al.12 The blood clearance parameters of the 
radioiodinated antibodies were fitted with a least squares minimization procedure, using the Macintosh 
Program Kaleidagraph (Synergy Software, Reading PA) and the following equation: X(t)  Aexp((alpha 
t))  Bexp((beta t)), where X(t) is the %ID/g of radiolabeled antibody at time t, as reported by Borsi et 
al.18 X0 was assumed to be equal to 40%, corresponding to a blood volume of 2.5 mL in each mouse.    
 
In vivo treatments   
For treatments, groups of 6 tumor-bearing mice (6-7 days after subcutaneous injection, when the tumors 
reached a volume of about 0.3-0.4 cm3) received injections in their tail vein of rmTNF and the purified 
fusion proteins in 100 L PBS. The control group received PBS only. Lyophilized melphalan (Alkeran; 
Glaxo Smith Kline, Research Triangle Park, NC) was reconstituted (5 mg/mL) in the solvent provided by the 
manufacturer immediately before use and, after further dilution in PBS, administered intraperitoneally (4.5 
g/g of mouse in 400 L). The weight of the animals and the tumor size were recorded at 24-hour intervals 
before and after treatments. The doubling time of the tumor size, (T  C)200%, in the treated (T) versus the 
untreated (C) mice, was calculated as reported by Bosslet et al.53 Toxicity was evaluated on the basis of 
weight loss. We considered a severe toxicity to be a more than 10% weight loss within 48 hours after a single 
intravenous injected dose, and an acceptable toxicity to be a lower than 5% weight loss within 48 hours after 
a single intravenous injected dose. We found that the weight loss was 0 or lower than 5% up to 1.5 pmol/g, 
with no significant differences between the 2 fusion proteins and rmTNF. In the therapeutic protocols with 
a single compound, 1 pmol/g L19mTNF, TN11mTNF, or mTNF was used, whereas 0.7 pmol/g was 
used in therapies combined with other drugs.    
 
Results    
Expression, purification, and characterization of L19mTNF and TN11mTNF fusion proteins   
For the preparation of L19mouse(m)TNF, we used the cDNA of the scFv L1912 and, for the control fusion 
protein TN11mTNF, the cDNA of the scFv TN11 (Figure 1A-B). TN11 is directed to the C repeat of 
human TN-C,47 which is not expressed in the tumor models used. As shown in Figure 1B, the cDNA 
corresponding to the open reading frame of mature murine TNF was appended to the 3 end of the 
cDNAof the scFvs by a linker of 45 bp. The cDNA constructs were cloned into the pcDNA3.1 mammalian 
expression vector used to transfect SP2/0 murine myeloma cells. The 2 fusion proteins were purified from 
the conditioned media of the transfected cells by affinity chromatography (described in “Materials and 
methods”), yielding about 3 mg/L for each fusion protein. The homotrimers were further purified by gel 
filtration. The fusion proteins were then analyzed in SDS-PAGE (Figure 1C), in which they migrated as 
monomers of the expected size of about 45 kDa. The gel filtration profiles (Superdex 200) showed a single 
peak for both, with a retention volume corresponding to the apparent molecular mass of homotrimers of 
about 140 kDa (Figure 1D). By dynamic light scattering measurements we obtained a molecular radius of 
4.819 nm for L19mTNF, corresponding to a molecular mass of 133.5 kDa, and of 4.835 nm for 
TN11mTNF, corresponding to a molecular mass of 134.4 kDa, confirming as expected that both fusion 
proteins were homotrimers. Both fusion proteins were tested for immunoreactivity of the scFv moiety by 
immunohistochemistry and ELISA, and the same immunoreactivity of the original scFvs with the respective 
antigens was found. Both fusion proteins were also evaluated for the biologic activity of the mTNF 
component by using a cytotoxic assay on L-M mouse fibroblasts. In this test we found that L19mTNF 
showed a 5 to 6 times higher activity than equimolar amounts of recombinant mTNF and of the fusion 
protein TN11mTNF (Figure 2A). This enhanced activity was explained by the fact that mouse L-M cells 
express B-FN, which leads to a concentration of TNF on the B-FN surrounding the cells, as demonstrated 
by immunocytochemistry using L19mTNF as primary antibody and an antibody to mTNF as secondary 
antibody (Figure 2Ba). When the binding of L19mTNF to the endogenous B-FN (Figure 2Bb) was 
inhibited by adding a large excess (150 g/mL) of L19scFv to L19mTNF, the biologic activity of 
equimolar amounts of L19mTNF, TN11mTNF, and rmTNF then became identical (Figure 2A).    
 
Biodistribution experiments   
For in vivo biodistribution experiments, L19mTNF and TN11mTNF were radioiodinated with I-125, as 
reported in “Materials and methods.” On gel filtration (Superdex 200) the profile of the radiolabeled fusion 
proteins was identical to that of unlabeled fusion proteins (Figure 1D), and the radioactivity recovery from 
the column was 100%, indicating that no molecular aggregation occurred.18 After radioiodination the 
immunoreactivity of L19mTNF was always more than 90%, as established by using ED-B/Sepharose 
affinity chromatography.18 Both L19mTNF and TN11mTNF retained more than 90% of the cytotoxic 
activity of the starting materials. The radioiodinated fusion proteins were intravenously injected (0.125 Ci 
[0.004625 MBq], 1.0 pmol/g, in 100 L PBS) in groups of F9 tumor-bearing mice; groups of 3 animals were 
killed at 3, 6, 24, and 48 hours after injection. The biodistribution results of the fusion proteins, expressed as 
the %ID/g of tissue, are summarized in Table 1 and compared with those of the dimeric scFv L19. Although 
125I-L19mTNF showed a very stable and high-level accumulation in tumors (Figure 3A), no accumulation 
of 125ITN11mTNF α was detected at any time point of the experiment (Figure 3B; Table 1). 
Microautoradiographies of tumors and different organs showed specific and selective accumulation of 
L19mTNF α  on tumor vasculature (Figure 3D), whereas no accumulation of TN11mTNF α  was 
detectable in the tumor or in any other organs. Figure 3C shows the curves of the F9 tumor-to-blood ratios of 
the %ID/g after intravenous injection of 125I-L19mTNF α , 125I-TN11mTNF α , and 125I-L19(scFv)2. 
Forty-eight hours after intravenous injection of 125I-L19mTNF α , this ratio had a value of 700, nearly 14 
times higher than the value obtained using the dimeric scFv L19. Blood clearance of L19mTNF α  was 
mediated mainly by way of the kidney, as determined by counting the urine samples, and showed a biphasic 
curve with an  and a   phase. Despite a molecular size of L19mTNF α  of nearly 140 kDa, its  and   
phase half-lives (T1/2  0.67 hour; T1/2   3.9 hours) were similar to those found for dimeric scFv 
L19 (T1/2  0.53 hour; T1/2   8 hours), which has a molecular mass of about 60 kDa, and much shorter 
than the complete L19IgG (T1/2  1.48 hours; T1/2   106.7 hours) which has a molecular mass of 
about 150 kDa.    
 
Therapeutic effects of L19mTNF α    
Groups of 3 F9 tumor-bearing mice were intravenously injected with 0.04, 0.25, and 1.0 pmol/g of the fusion 
proteins L19mTNF α  and TN11mTNF α . The control group received PBS. The animals were killed 1 
hour, 5 hours, and 24 hours after treatment. Healthy organs (lung, spleen, liver, kidney, intestine, and heart) 
were studied histologically to reveal side effects as a result of TNF α  toxicity. With the exception of small 
foci of hemorrhages in the lung of all treated mice 5 hours and 24 hours after treatment, no morphologic side 
effects were found. One hour from injection of 1.0 pmol/g, the tumor cell viability (described in “Materials 
and methods”) was 90% in the tumors treated with TN11mTNF α  and 62% in the tumors treated with 
L19mTNF α . These values decreased after 24 hours to about 30% in the tumors treated with 
TN11mTNF and to less than 6% in the tumors treated with L19mTNF α  (Figure 4A). In the remaining 
vital tumor tissue, the vascular density and the cellular proliferation (Ki-67 index) were not affected. 
Twenty-four hours after L19mTNF α  treatment, numerous apoptotic endothelial cells were demonstrated 
in the vessels of the vital tumor tissue (described in “Materials and methods”), whereas no apoptotic 
endothelial cells were detected in the vessels of the untreated control tumors (Figure 4B). Figure 4C shows 
the F9 tumor growth curves in mice treated with intravenous injection of 1.0 pmol/g L19mTNF α , 
TN11mTNF α , and mTNF α . The animals were treated when the tumors were about 0.4 cm3. In the 
PBS-treated group of control mice, the tumor volume doubling time was about 20 hours, whereas the tumor 
volume of the animals treated with L19mTNF α  remained stable for about 4 days, and then the growth 
curve presented a slope similar to that of the tumors of untreated animals. This finding is consistent with the 
results shown in Figure 4A, showing that a single injection of 1 pmol/g L19mTNF α  reduces the vital part 
of the tumor to about 5%.. In fact, considering that this 5% of the vital tumors still conserves a doubling time 
of 20 hours, it should reach the original volume in about 4 days, after which time it resumes the growth curve 
of the untreated controls. Tumor growth rate in the 3 groups of treated mice was evaluated by calculating the 
tumor doubling time53 with respect to the PBS-treated controls. The results, depicted in Figure 4D, clearly 
show no significant differences between TN11mTNF α  and rmTNF α , whereas L19mTNF α  was at 
least 4 times more active. In fact, a 4-fold higher dose of both rmTNF α  and TN11mTNF α  was 
necessary to achieve a response similar to that of L19mTNF α . No significant weight loss was observed in 
the treated animals.    
 
Therapeutic effects of L19mTNF α  in combination with L19-IL2   
L19-IL2 is a recently reported fusion protein composed of the scFv L19 and interleukin 2.22 Because of the 
targeting ability of L19, L19-IL2 concentrates IL2 in tumors and, therefore, enhances the cytokine’s 
therapeutic index.22 We performed biodistribution studies in F9 tumor-bearing mice by using 0.5 g/g 
radioiodinated L19-IL2, administered intravenously with and without 0.7 pmol/g unlabeled L19mTNF α  
or unlabeled TN11mTNF α . No specific accumulation was found in healthy organs at any time when 
125I-L19-IL2 was injected alone or in combination with unlabeled L19mTNF α  or TN11mTNF α  (data 
not shown). 125I-L19-IL2 accumulation in F9 tumors was significantly more persistent and at high levels 
when it was co-injected with L19mTNF α  (about 12%ID/g between 3 and 48 hours) than when given 
alone or in combination with TN11mTNF α  (Figure 5A). This persistently high accumulation in tumors 
accounted for the tumor-to-blood ratio of the %ID/g of 250 at 48 hours when 125I-L19-IL2 was co-injected 
with unlabeled L19mTNF α , whereas, after the same time, it was less than 50 when 125I-L19-IL2 was 
injected alone or with unlabeled TN11mTNF α  (Figure 5C). The effects of a combined systemic therapy 
using L19mTNF α  and L19-IL2 are shown in Figure 5D. Groups of 6 F9 tumorbearing mice received 
intravenous treatments at day 7 and 10 after subcutaneous inoculation of the F9 tumor cells, when the tumor 
was about 0.3 cm3. The treatments entailed intravenous injections of 1 g/g L19-IL2 combined with 0.7 
pmol/g L19mTNF α or TN11mTNF α . The animals’ weight loss was always less than 5%. As depicted in 
Figure 5D, the tumors in animals treated with the combination L19-IL2 and L19mTNF α  grew at a much 
slower rate compared with the tumors in the other groups of mice. In fact, tumors in mice receiving the 2 
L19 fusion proteins showed no increase in size up to 15 days after tumor grafting.    
 
Therapeutic effects of L19mTNF α  in combination with melphalan   
Melphalan is an alkylating compound widely used in combination with TNF α  in the isolated limb 
perfusion treatment of melanomas and soft tissue sarcomas.33,38,39,54 The aim of the experiment was to 
establish whether a higher therapeutic synergy than that already described could be achieved by substituting 
TNF α  with L19mTNF α . Groups of 6 F9 tumor-bearing mice were given a single intravenous injection 
of 0.7 pmol/g L19mTNF α , of the control fusion protein TN11mTNF α , and of rmTNF α  on day 6 
after tumor grafting, followed by intraperitoneal injection of 4.5 g/g melphalan 24 hours later. The tumor 
growth curves of animals treated with PBS, PBS and melphalan, rmTNF α  and melphalan, TN11mTNF α 
 and melphalan, and L19mTNF α  and melphalan are depicted in Figure 6A. All the treatments, including 
melphalan alone, reduced the tumoral mass within 2 to 3 days. However, although treatment with melphalan 
alone or in combination with rmTNF α  or TN11mTNF α  induced tumor quiescence up to day 16 to 18 
after tumor cell grafting and thereafter produced a growth slope similar to that seen in the PBS-treated 
control group, the tumors of mice treated with melphalan and L19mTNF α  were quiescent up to 25 to 26 
days after tumor cell grafting. Similar results were obtained by using different tumor models such as WHEI-
164 fibrosarcoma (Figure 6B) and C51 colon adenocarcinoma (data not shown).    
 
Discussion   
TNFα is one of the most potent antitumor cytokines known. Therapeutically effective doses of TNF α  
cannot be given systemically, however, because of its unacceptably toxic side effects. As a result, the clinical 
use of TNF α  has until now been limited to locoregional applications. In particular, the use of TNF α  in 
ILP was authorized in combination with melphalan by the European Agency for the Evaluation of Medicinal 
Products (EMEA) for the treatment of nonresectable, high-grade sarcomas,39,54 and the American College 
of Physicians approved a phase 3 clinical trial using melphalan with or without TNF α for the ILP of 
melanomas.38,55 TNF α  is also being evaluated for the therapy of nonresectable liver tumors by isolated 
hepatic perfusion.56 The selective targeted delivery of TNF α  to tumors seems to provide an appealing 
strategy that could ultimately lead to its systemic use, because it would achieve the purpose of selectively 
concentrating the cytokine to elicit a significant antitumoral activity in primary and disseminated tumors 
while limiting systemic toxicity. The effective targeting of tumors, however, has 2 main requisites: (1) a 
target in the tumor that is specific, abundant, stable, and readily available for ligand molecules coming from 
the bloodstream; and (2) a ligand molecule with suitable pharmacokinetic properties to allow its diffusion 
from the bloodstream to the tumor and with a high affinity for the target to ensure its efficient and selective 
accumulation in the tumor. We have chosen to selectively deliver therapeutic agents to tumor ECM 
components, which are generally more abundant and stable with respect to tumor-associated cell surface 
antigens.1 The tumor microenvironment can be considered a possible pantumoral target; in fact, tumor 
progression induces (and subsequently needs) significant modifications in tumor microenvironment 
components, particularly those of the tumor ECM, that differ both quantitatively and qualitatively from those 
of the healthy ECM. Many of these tumor ECM components are shared by all solid tumors, accounting for 
general properties and functions such as cell invasion (both healthy cells into tumor tissues and cancer cells 
into healthy tissues) and angiogenesis. Of the numerous molecules constituting the modified tumor ECM, we 
focused our attention on B-FN. B-FN is widely expressed in the ECM of all solid tumors thus far tested and 
is constantly associated with angiogenic processes,10,11 but it is otherwise undetectable in healthy adult 
tissues.5 These features make B-FN a potentially ideal tumor target, also because the targeted delivery of 
therapeutic agents to the subendothelial ECM overcomes problems associated with the interstitial 
hypertension of solid tumors.57 Today, some of the most promising ligands are the human antibody 
molecules that can be generated and customized by using molecular engineering technologies. We have 
produced L19,12-14 an scFv with a high affinity (Kd  5.4  1011 M) for the ED-B domain of FN, and 
demonstrated in vivo that it selectively and efficiently accumulates around tumor neovasculature and is able 
to selectively transport to and concentrate in the tumor mass any one of a number of therapeutic molecules to 
which it is conjugated.20-23 The ability of L19 to selectively target tumors has also been demonstrated in 
patients using scintigraphic techniques.19 Here we report the preparation, characterization, and preclinical 
therapeutic evaluation of the fusion protein L19mTNF α . We expressed this fusion protein in mammalian 
cells and purified it as an immunoreactive and biologically active homotrimer. Already in in vitro assays 
using L-M mouse fibroblasts we observed an increased toxic activity of L19mTNF α  compared with 
rmTNF α  and with the control fusion protein TN11mTNF α , because of the selective binding of 
L19mTNF α  to B-FN present in the ECM of cultured L-M cells (Figure 2). Inhibition of L19mTNF α  
binding to B-FN present in the ECM of the cultured cells by competition with scFv L19 offset the higher 
toxicity of L19mTNF α  (Figure 2). This experiment demonstrates that TNF α , in particular, and 
cytokines, in general, can exert their biologic activity if delivered directly to the ECM. Cells, both in vitro 
and in vivo, constitute a dynamic system in which they migrate along ECM structures that, in our case, are 
armed with TNF α ; as such, cell receptors come into contact with the cytokine, which is thus able to 
exercise its biologic activity. In particular, it is known that TNF α  is toxic for tumor endothelial cells and 
that, within a tumor, endothelial cells migrate along ECM structures containing B-FN.12 Thus, delivery of 
TNF α  to the tumor ECM creates a sort of “minefield” that should prove lethal for invading endothelial 
cells, thus leading to antitumoral effects. The results obtained in biodistribution experiments with the 
radiolabeled L19mTNF α  in the syngeneic murine tumor model F9 showed that this fusion protein 
accumulates more persistently and at higher levels in the tumor than scFv L19 (more than 10% of the ID/g, 
48 hours after injection of the radiolabeled fusion protein) (Table 1; Figure 3). Moreover, despite its 
molecular mass of nearly 140kDa, L19mTNF α  shows a much faster blood clearance rate than molecules 
of similar size, such as the complete L19IgG (described in “Results”). Similar observations were reported by 
Gillies et al43 and Rosenblum et al,58 who found that when fused or conjugated to TNF α , a monoclonal 
antibody presented a more rapid  phase of clearance than the monoclonal antibody alone, very likely as a 
result of microvascular leakage59 and to reduced interstitial tumor pressure34 induced by TNF α . In our 
syngeneic murine tumor models the antibody-mediated delivery of TNF α  to the subendothelial ECM 
clearly enhanced the therapeutic performance of TNF α . F9 tumor-bearing mice, 24 hours after 
intravenous treatment with a single dose of L19mTNF α , showed a remarkable tumor necrosis (about 95% 
of the total tumor tissue, Figure 4A). Tumor necrosis was accompanied by thrombosis, vascular ectasia, and 
hemorrhaging, features that are produced by the activity of TNF α  on the angiogenic endothelial cells as 
clearly demonstrated in earlier studies.26-33 Furthermore, we observed that in numerous vessels of the vital 
part of the tumor, many endothelial cells undergo apoptosis that was not detected in the vessels of the control 
tumors (Figure 4B). Induction of tumor necrosis as well as inhibition of tumor growth by L19mTNF α  
was at least 4 times higher compared with both the control fusion protein TN11mTNF and rmTNF. 
Because we used a human (L19)–mouse (TNF α ) chimeric fusion protein, repeated intravenous injections 
induced production of large amounts of mouse antibodies to the human part of the fusion protein (L19) that 
correlated with a reduced antitumor activity of the fusion protein (data not shown). Studies to demonstrate 
the neutralizing activity of these antibodies are under way. The most dramatic therapeutic results were 
achieved by treating tumor-bearing mice with L19mTNF α  in combination with melphalan or L19-IL2.We 
recently reported on the enhancement of the antitumor properties of IL2 when delivered in the format of 
fusion protein L19-IL2.22 L19-IL2 administered in combination with L19mTNF α  accumulates more 
persistently within the tumor than does L19-IL2 alone or in combination with TN11mTNF α  (Figure 5A-
C). Such higher and more persistent accumulations ultimately lead to enhanced therapeutic performance 
(Figure 5D). The synergistic antitumor effect of TNF α  and melphalan38,39 derives from the effects on 
tumor vasculature of TNF, which reduces tumor interstitial pressure and increases34 vascular permeability, 
36 ultimately leading to a higher melphalan accumulation.35 Synergy between L19mTNF α  and 
melphalan was dramatically higher than that between TN11mTNF α  or rmTNF α  and melphalan 
(Figure 6A-B), thus demonstrating that the therapeutic effects depend on TNF α  concentration in the 
tumor. In conclusion, we have shown that the L19mTNF α  fusion protein is a potent bioactive molecule. 
Because B-FN is a naturally occurring marker of angiogenesis and of tissue remodeling, antigenically 
identical in mouse and human and present in similar amounts in human tumors and in murine tumor 
models,22 L19mTNF α  alone or in combination with different antineoplastic drugs may open new 
perspectives for the systemic use of TNF α for anticancer therapy.   
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